Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities.
In this paper a patient with a non-Hodgkin's lymphoma (NHL) and paraneoplastic pemphigus (PNP) is described. PNP is a very rare, painful mucocutaneous intraepithelial blistering disease associated with occult or confirmed malignancy. Patients with PNP show severe, progressive mucocutaneous disease with a high mortality rate, because of drug-induced infectious complications. The patients sometimes benefit from high doses of oral corticosteroids. However, pulse therapy with high doses of prednisolone (or dexamethasone) in combination with other immunosuppressants induces variable and inconstant results. Intravenous immunoglobulin (IVIg) has been applied in different cases of PNP with encouraging results. Plasmapheresis or plasma exchange (PE) in combination with corticosteroids and/or cyclophosphamide or azathioprine showed similar rapid and beneficial results in association with decreasing auto-antibody levels in this group of refractory pemphigus. Another interesting therapeutic option is rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B-lymphocytes. Administration of rituximab for patients with PNP in combination with follicular NHL is not always successful regarding oral lesions as we report in this case. PE leading to prompt depletion of autoreactive antibodies combined with immunosuppressants or synchronisation of PE with IVIg seems the best treatment modality for this refractory group, but the therapeutic value and appropriate timing of rituximab obviously deserve further evaluation in patients with low grade NHL and PNP.
Rossum
M M Van
MM
Department of Dermatology, University Medical Centre Nijmegen, Nijmegen, The Netherlands. m.vanrossum@derma.umcn.nl
Verhaegen
N T M
NT
Jonkman
M F
MF
Mackenzie
M A
MA
Koster
A
A
Van Der Valk
P G M
PG
Span
L F R
LF
D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000368:Aged; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000494:pharmacology; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000494:pharmacology; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D001379:Azathioprine / Q000494:pharmacology; D001402:B-Lymphocytes / Q000378:metabolism; D003520:Cyclophosphamide / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D010257:Paraneoplastic Syndromes / Q000188:drug therapy; D010392:Pemphigus / Q000188:drug therapy; D010951:Plasma Exchange; D011239:Prednisolone / Q000494:pharmacology; D011379:Prognosis; D000069283:Rituximab; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003907:Dexamethasone; D003520:Cyclophosphamide; D011239:Prednisolone; D001379:Azathioprine